2024
Second primary non-breast cancers in young breast cancer survivors
Zhang B, Brantley K, Rosenberg S, Kirkner G, Collins L, Ruddy K, Tamimi R, Schapira L, Borges V, Warner E, Come S, Winer E, Bellon J, Partridge A. Second primary non-breast cancers in young breast cancer survivors. Breast Cancer Research And Treatment 2024, 207: 587-597. PMID: 38858235, DOI: 10.1007/s10549-024-07400-z.Peer-Reviewed Original ResearchPrimary non-breast cancerNon-breast cancerSubdistribution hazard ratiosYoung breast cancer survivorsStage 0-III BCBreast cancer survivorsConfidence intervalsGray subdistribution hazard modelRisk factorsMedical record reviewPrimary BCBreast cancerCumulative incidenceBC survivorsCancer survivorsYoung breast cancerSubdistribution hazard modelPrimary tumor characteristicsMedian follow-upRecord reviewType of malignancyGermline geneticsHazard ratioLong-term surveillancePatient factors
2013
Breast cancer presentation and diagnostic delays in young women
Ruddy KJ, Gelber S, Tamimi RM, Schapira L, Come SE, Meyer ME, Winer EP, Partridge AH. Breast cancer presentation and diagnostic delays in young women. Cancer 2013, 120: 20-25. PMID: 24347383, DOI: 10.1002/cncr.28287.Peer-Reviewed Original ResearchConceptsCare delaysSymptoms of cancerBreast cancerFirst visitYoung womenMulticenter cohort studyMedical record reviewPatient's first visitBreast cancer presentationBreast abnormalitiesFirst signOwn breast cancerHealth care providersMost young womenPoor financial statusCancer presentationCohort studyDiagnostic delayRecord reviewTumor characteristicsPoor outcomeSystemic symptomsDisease stageEligible participantsExamination abnormalitiesPersonalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice
Ruddy KJ, Desantis SD, Gelman RS, Wu AH, Punglia RS, Mayer EL, Tolaney SM, Winer EP, Partridge AH, Burstein HJ. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice. Breast Cancer Research And Treatment 2013, 141: 421-427. PMID: 24062210, DOI: 10.1007/s10549-013-2700-1.Peer-Reviewed Original ResearchConceptsEndoxifen levelsEndocrine therapyBreast cancerCYP2D6 genotypeAdjuvant tamoxifenTamoxifen metabolismOptimal adjuvant endocrine therapyAlternative endocrine therapyBaseline whole bloodAdjuvant endocrine therapyMedical record reviewActual treatment decisionsPoor metabolizer genotypeCytochrome P450 2D6Record reviewClinical evidenceTreatment recommendationsTherapy recommendationsTreatment decisionsEstrogen receptorHormonal treatmentStage IClinical practicePatientsTamoxifen